Veru Inc. (NASDAQ:VERU - Free Report) - Investment analysts at B. Riley reduced their Q4 2025 earnings estimates for Veru in a research report issued to clients and investors on Wednesday, May 14th. B. Riley analyst W. Wood now forecasts that the company will earn ($0.06) per share for the quarter, down from their previous forecast of ($0.05). The consensus estimate for Veru's current full-year earnings is ($0.22) per share. B. Riley also issued estimates for Veru's FY2026 earnings at ($0.24) EPS.
Veru (NASDAQ:VERU - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%.
Veru Stock Up 1.8%
NASDAQ VERU traded up $0.01 during trading hours on Monday, reaching $0.50. 948,126 shares of the company were exchanged, compared to its average volume of 1,721,061. Veru has a 1 year low of $0.45 and a 1 year high of $1.42. The business's 50 day simple moving average is $0.53 and its 200-day simple moving average is $0.61. The stock has a market capitalization of $73.07 million, a P/E ratio of -1.92 and a beta of -0.74.
Hedge Funds Weigh In On Veru
Large investors have recently modified their holdings of the company. Weaver Consulting Group raised its stake in shares of Veru by 27.4% during the first quarter. Weaver Consulting Group now owns 88,838 shares of the company's stock worth $44,000 after acquiring an additional 19,133 shares in the last quarter. Wells Fargo & Company MN increased its position in Veru by 37.1% during the 4th quarter. Wells Fargo & Company MN now owns 75,512 shares of the company's stock valued at $49,000 after purchasing an additional 20,430 shares during the period. Integrated Wealth Concepts LLC increased its position in Veru by 31.3% during the 4th quarter. Integrated Wealth Concepts LLC now owns 85,900 shares of the company's stock valued at $56,000 after purchasing an additional 20,500 shares during the period. Gladstone Institutional Advisory LLC grew its position in shares of Veru by 52.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 86,876 shares of the company's stock worth $57,000 after buying an additional 30,000 shares during the period. Finally, Cetera Investment Advisers boosted its stake in Veru by 26.1% in the 4th quarter. Cetera Investment Advisers now owns 95,210 shares of the company's stock worth $62,000 after purchasing an additional 19,724 shares in the last quarter. 47.16% of the stock is currently owned by institutional investors.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Further Reading
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
